8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
Deep-dive into cost-effectiveness analyses derived from the Fracture Intervention Trial (FIT), examining cost per QALY for alendronate, payer-coverage dynamics, and the real-world value calculation for patients considering bisphosphonate therapy.
Deep-dive into the FIT extension (FLEX) and long-term follow-up data for alendronate, covering durability of fracture protection, rebound risk after discontinuation, and late-emerging safety signals.
A deep-dive into the Fracture Intervention Trial's primary and secondary endpoints for alendronate in postmenopausal osteoporosis, including effect sizes, confidence intervals, subgroup analyses, and the time-course pattern of fracture reduction.
Deep-dive into the FIT trial's pre-specified and post-hoc subgroup analyses for alendronate, examining differential fracture reduction by age, baseline BMD, prior fracture status, BMI, and biomarkers.
A deep-dive overview of the Fracture Intervention Trial (FIT), the landmark 1998 JAMA study that proved alendronate reduces vertebral fractures by 47% in postmenopausal women with osteoporosis.
A critical appraisal of the FIT trial for alendronate, examining enrollment biases, follow-up duration, generalizability gaps, statistical caveats, and conflict-of-interest concerns.
A deep methodological analysis of the FIT trial (1998 JAMA), examining how randomization, blinding, endpoint definitions, and statistical choices shaped the 47% vertebral fracture reduction finding for alendronate.
A deep-dive into the Fracture Intervention Trial (FIT) of alendronate: methodology, real results, limitations, and what this foundational bisphosphonate trial means for prescribing decisions today.